← Back to Screener
Myriad Genetics Inc (MYGN)
Price$5.00
Favorite Metrics
Price vs S&P 500 (26W)-36.05%
Price vs S&P 500 (4W)6.03%
Market Capitalization$480.16M
All Metrics
P/CF (Annual)266.76x
Book Value / Share (Quarterly)$3.94
P/TBV (Annual)2.67x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)6.72%
Cash Flow / Share (Quarterly)$-0.27
Price vs S&P 500 (YTD)-18.25%
Gross Margin (TTM)69.93%
Net Profit Margin (TTM)-44.38%
EPS (TTM)$-3.95
10-Day Avg Trading Volume1.05M
EPS Excl Extra (TTM)$-3.95
Revenue Growth (5Y)22.43%
EPS (Annual)$-3.95
ROI (Annual)-74.99%
Gross Margin (Annual)69.93%
Net Profit Margin (5Y Avg)-23.00%
Cash / Share (Quarterly)$1.60
Revenue Growth QoQ (YoY)-0.38%
ROA (Last FY)-51.78%
Revenue Growth TTM (YoY)-1.56%
EBITD / Share (TTM)$-3.59
ROE (5Y Avg)-33.33%
Operating Margin (TTM)-46.96%
Cash Flow / Share (Annual)$-0.27
P/B Ratio1.30x
P/B Ratio (Quarterly)1.56x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.55x
Net Interest Coverage (TTM)-44.41x
ROA (TTM)-46.94%
EV / EBITDA (TTM)58.50x
EPS Incl Extra (Annual)$-3.95
Current Ratio (Annual)2.49x
Quick Ratio (Quarterly)1.98x
3-Month Avg Trading Volume1.45M
52-Week Price Return-35.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.30
P/S Ratio (Annual)0.58x
Asset Turnover (Annual)1.17x
52-Week High$8.59
Operating Margin (5Y Avg)-24.72%
EPS Excl Extra (Annual)$-3.95
CapEx CAGR (5Y)21.85%
Tangible BV CAGR (5Y)-6.76%
26-Week Price Return-32.07%
Quick Ratio (Annual)1.98x
13-Week Price Return-21.00%
Total Debt / Equity (Annual)0.33x
Current Ratio (Quarterly)2.49x
Enterprise Value$450.464
Revenue / Share Growth (5Y)17.37%
Asset Turnover (TTM)1.06x
Book Value / Share Growth (5Y)-19.56%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)8.53x
Pretax Margin (Annual)-47.92%
Cash / Share (Annual)$1.60
3-Month Return Std Dev58.02%
Gross Margin (5Y Avg)70.01%
Net Income / Employee (TTM)$-0
ROE (Last FY)-99.43%
Net Interest Coverage (Annual)-44.41x
EPS Basic Excl Extra (Annual)$-3.95
P/FCF (TTM)24.62x
Receivables Turnover (TTM)6.97x
Total Debt / Equity (Quarterly)0.33x
EPS Incl Extra (TTM)$-3.95
Receivables Turnover (Annual)6.97x
ROI (TTM)-66.77%
P/S Ratio (TTM)0.58x
Pretax Margin (5Y Avg)-25.29%
Revenue / Share (Annual)$8.90
Tangible BV / Share (Annual)$2.30
Forward P/E155.82x
Price vs S&P 500 (52W)-65.60%
Year-to-Date Return-15.61%
5-Day Price Return16.89%
EPS Normalized (Annual)$-3.95
ROA (5Y Avg)-19.71%
Net Profit Margin (Annual)-44.38%
Month-to-Date Return15.33%
Cash Flow / Share (TTM)$-2.62
EBITD / Share (Annual)$-3.59
Operating Margin (Annual)-46.96%
LT Debt / Equity (Annual)0.33x
P/CF (TTM)266.76x
ROI (5Y Avg)-27.93%
LT Debt / Equity (Quarterly)0.33x
EPS Basic Excl Extra (TTM)$-3.95
P/TBV (Quarterly)2.67x
P/B Ratio (Annual)1.56x
Inventory Turnover (TTM)8.53x
Pretax Margin (TTM)-47.92%
Book Value / Share (Annual)$3.94
Price vs S&P 500 (13W)-21.69%
Beta1.92x
P/FCF (Annual)2400.82x
Revenue / Share (TTM)$8.82
ROE (TTM)-79.81%
52-Week Low$3.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.67
2.67
2.67
2.67
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MYGNMyriad Genetics Inc | 0.58x | -1.56% | 69.93% | — | $5.00 |
IDXXIdexx Laboratories Inc | 10.59x | 10.42% | 61.80% | 14.28% | $569.95 |
LNTHLantheus Holdings, Inc | 3.53x | 0.50% | 61.10% | 40.71% | $83.92 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 299.06x | -5.72% | 89.00% | — | $27.80 |
CLDXCelldex Therapeutics, Inc | 1718.98x | -77.98% | 17.65% | — | $33.86 |
NEOGNeogen Corp | 2.32x | -3.91% | 45.20% | — | $9.24 |
NTLAIntellia Therapeutics, Inc | 26.08x | 16.92% | — | — | $14.16 |
QDELQuidelOrtho Corporation Common Stock | 0.31x | -1.89% | 46.67% | — | $12.69 |
ACHVAchieve Life Sciences, Inc. | 14.37x | -89.25% | — | — | $4.81 |
TKNOAlpha Teknova, Inc. Common Stock | 3.62x | 7.35% | 33.17% | — | $2.68 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 27.84x | 115.58% | 56.97% | — | $3.51 |
About
Myriad Genetics develops and commercializes molecular diagnostic tests that assess disease risk and guide treatment decisions across medical specialties. The company's portfolio includes BRACAnalysis CDx, GeneSight, MyChoice CDx, Prolaris, and other proprietary tests used to support earlier detection and precision treatment. Revenue is primarily generated in the United States with international operations.